Angela di Leo from the Hospital of Prato, Italy, presented results from the large Phase III CONFIRM trial of the synthetic oestrogen receptor antagonist fulvestrant in postmenopausal women with advanced, hormone receptor positive breast cancer. Here, NR4A1 is linked to breast carcinoma.